ALSO NOTED: UT hospital bans pharma promos;FDA approves Abbott HIV drug for kids;

> The University of Texas Health Science Center in San Antonio is readying a conflicts-of-interest policy that will ban all gifts from the drug industry, no matter how small. Report

> The FDA gave its blessing to a child-sized dose of the anti-HIV drug Kaletra, made by Abbott Laboratories. The company plans to launch the medication for kids in the U.S. this month. Report

> Cardiogenesis got the FDA's nod for a robotic device for laser hear surgery. Report

> AstraZeneca tapped Kenneth L. Murtha as regional supply VP for the Americas; he had been vice president for business operations in the U.S. Report

> San Francisco's non-profit pharma, the Institute for OneWorld Health, has hired Nina Grove as vice president; Grove had been director of commercial regulatory affairs at Genentech. Report

> Schering-Plough hired the Swedish construction company Skanska to oversee the $60 million expansion of a Summit, New Jersey, facility. Report

> Humacyte has had some success developing material that can be used to craft new blood vessels. Report

> Scientists at Oklahoma Medical Research Foundation are reporting success in advancing an experimental, preclinical vaccine that can prevent or slow Alzheimer's. Report

> The Independent is reporting that scientists at the Oregon National Primate Research Center are on the verge of announcing that they have developed a new technique for cloning embryos from adult monkeys. Report

> Cytogen says that CEO Michael Becker has handed in his walking papers in order to "pursue another executive position." Report

> Alabama is betting $65 million that its new HudsonAlpha Institute for Biotechnology in Huntsville will prove the launch pad for a burgeoning new biotech industry. Report

And Finally... Can you be too clean? If you use antimicrobial soap, you may be speeding the evolution of supergerms. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.